IP Library › Granted Patent US 12,102,624
Granted Patent B2
US 12,102,624 · App. 17/446,063 · Granted Oct 1, 2024

Pantoprazole compositions and methods

Inventors: Brijeshkumar B. Pandya (Sacramento, CA); Govind R. Jagadale (Sacramento, CA); Dasaradhi Lakkaraju (Sacramento, CA); Bala Tripura Sundari Chodavarapu (Davis, CA); Anand Shukla (Denver, CO); Jwalant Shukla (Sacramento, CA)
Assignee: Nivagen Pharmaceuticals, Inc.
A61K31/4439A61J1/10A61K9/1611A61K9/1694
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,102,624
App. No.
17/446,063
Granted
Oct 1, 2024
Kind
B2
Abstract

A spray-dried storage stable pantoprazole composition is provided. The pantoprazole composition includes a pantoprazole and an excipient matrix including sodium chloride (NaCl). The pantoprazole is substantially uniformly dispersed in the excipient matrix. A method for forming a storage stable pantoprazole composition is also provided. The method includes combining a bulking agent and water to form a first solution, combining a pantoprazole and the first solution to form a second solution, combining sodium hydroxide and the second solution to form a bulk solution, and removing water from the bulk solution by drying to form the storage stable pantoprazole composition.

Claims (37)

1. A spray-dried storage stable pantoprazole composition comprising:

pantoprazole; and

an excipient matrix comprising sodium chloride (NaCl), wherein the sodium chloride and the pantoprazole are present at a weight ratio of between 50:1 and 5:1;

wherein the pantoprazole is substantially uniformly dispersed in the excipient matrix; and

wherein the pantoprazole composition is storage stable such that, after storage at 25° C. and 40% relative humidity for 12 weeks, the composition contains equal or less than 0.20% by weight of a pantoprazole sulfone degradant (Impurity-A) and equal or less than 0.20% by weight of a pantoprazole Methyl degradant (Impurity-D&F).

2. The storage stable pantoprazole composition of claim 1 , wherein the pantoprazole is in form of pantoprazole sodium sesquihydrate.

3. The storage stable pantoprazole composition of claim 1 , wherein the pantoprazole and the sodium chloride are present in a weight ratio of about 1:11 or about 1:22.

4. The storage stable pantoprazole composition of claim 1 , wherein the excipient further comprises a compound selected from the group consisting of a salt other than sodium chloride, an amino acid, and a sugar.

5. The storage stable pantoprazole composition of claim 1 , wherein the composition, after storage at 25° C. and 40% relative humidity for 12 weeks, contains equal or less than 0.1% by weight of a pantoprazole sulfone degradant based on a total weight of the composition.

6. A kit comprising:

a. a storage stable pantoprazole composition according to claim 1 ;

b. a liquid phase; and

c. a container that separately contains the pantoprazole composition and the liquid phase.

7. The kit of claim 6 , wherein the container comprises a first pouch and wherein the storage stable pantoprazole composition is contained in a first chamber of the first pouch comprising a polymeric material.

8. The kit of claim 7 , wherein the container comprises a second pouch and wherein the liquid phase is contained is contained in a second chamber of the second pouch comprising a polymeric material, wherein the first pouch and the second pouch are coupled together, and wherein the first chamber and the second chamber are fluidly isolated from each other.

9. The kit of claim 6 , wherein the storage stable pantoprazole composition is present in an amount of from about 20 to about 100 mg.

10. The kit of claim 6 , wherein the liquid phase comprises water.

11. The kit of claim 6 , wherein the liquid phase is present in an amount of from about 10 to about 200 mL.

12. A method for forming a storage stable pantoprazole composition, comprising:

combining a bulking agent and water to form a first solution;

combining pantoprazole and the first solution to form a second solution;

combining sodium hydroxide and the second solution to form a bulk solution; and

removing water from the bulk solution by a spray-dry process to form the storage stable pantoprazole composition;

wherein the bulking agent and the pantoprazole are present in the storage stable pantoprazole composition at a weight ratio of between 50:1 and 5:1; and

wherein the pantoprazole composition is storage stable such that, after storage at 25° C. and 40% relative humidity for 12 weeks, the composition contains equal or less than 0.20% by weight of a pantoprazole sulfone degradant (Impurity-A) and equal or less than 0.20% by weight of a pantoprazole Methyl degradant (Impurity-D&F).

13. The method of claim 12 , wherein the spray dry process is selected from the group consisting of spray-drying, spray solidification, and spray pilling.

14. The method of claim 12 , wherein the bulking agent comprises a compound selected from the group consisting of a salt, an amino acid, and a sugar.

15. The method of claim 14 , wherein:

a. the salt is selected from the group consisting of sodium chloride (NaCl), magnesium chloride (MgCl2), and calcium chloride (CaCl2);

b. the amino acid comprises glycine;

c. the sugar comprises dextrose, sucrose, trehalose, or combinations thereof; or

d. any combination of a. through c.

16. The method of claim 12 , wherein the sodium hydroxide is combined with the second solution in an amount sufficient for the bulk solution to have a pH of from about 8 to about 10.

17. The method of claim 12 , wherein the step of combining the sodium hydroxide and the second solution is further defined as forming a third solution, and wherein the method further comprises combining a solvent and the third solution to form the bulk solution.

18. The method of claim 17 , wherein the solvent comprises acetone.

19. The method of claim 12 , wherein the water combined with the bulking agent has a temperature of from about 1° C. to about 10° C.

20. The method of claim 12 , wherein the water combined with the bulking agent has a temperature of from about 15° C. to about 30° C.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT APPLICATION NO. 17/466,063 PREVIOUSLY RECORDED AT REEL: 60657 FRAME: 158. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded May 10, 2024
From: NIVAGEN PHARMACEUTICALS, INC.
To: CORBEL CAPITAL PARTNERS SBIC, L.P.
Reel/Frame 067531/0287 →
SECURITY INTEREST Recorded Jul 28, 2022
From: NIVAGEN PHARMACEUTICALS, INC.
To: CORBEL CAPITAL PARTNERS SBIC, L.P.
Reel/Frame 060657/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2021
From: PANDYA, BRIJESHKUMAR B.; JAGADALE, GOVIND R.; LAKKARAJU, DASARADHI; CHODAVARAPU, BALA TRIPURA SUNDARI; SHUKLA, ANAND; SHUKLA, JWALANT
To: NIVAGEN PHARAMACEUTICALS, INC.
Reel/Frame 057302/0916 →
Continuity (2)
Provisional Application 63070510 · Aug 26, 2020
Related Publication 20220062253A1 · Mar 3, 2022